Insmed Abandons Brensocatib for Hidradenitis Suppurativa After Phase 2b Failure
Event summary
- Insmed's Phase 2b CEDAR study for brensocatib in hidradenitis suppurativa failed to meet primary or secondary endpoints.
- Both 10 mg and 40 mg doses of brensocatib showed lower reductions in abscess and inflammatory nodule counts compared to placebo.
- The study enrolled 214 patients across 72 global sites, with no new safety signals identified.
- Insmed will discontinue brensocatib development for HS and present data at a future congress.
The big picture
The failure of brensocatib in HS highlights the challenges of developing treatments for complex inflammatory diseases with limited preclinical models. Insmed's decision to discontinue the program reflects the high stakes of clinical development, where even late-stage trials can fail to meet efficacy benchmarks. The company's focus on pulmonary and inflammatory conditions remains, but this setback may prompt a strategic review of its mid-to-late-stage pipeline.
What we're watching
- Pipeline Reallocation
- How Insmed will repurpose resources from the discontinued HS program to other pipeline assets.
- Scientific Insights
- Whether data from the CEDAR study will inform future HS research or other inflammatory conditions.
- Investor Sentiment
- The impact of this setback on Insmed's stock performance and investor confidence.
Related topics